<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Med</journal-id><journal-title>BMC Medicine</journal-title><issn pub-type="epub">1741-7015</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19144173</article-id><article-id pub-id-type="pmc">2636836</article-id><article-id pub-id-type="publisher-id">1741-7015-7-2</article-id><article-id pub-id-type="doi">10.1186/1741-7015-7-2</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Puhan</surname><given-names>Milo A</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I2">2</xref><email>mpuhan@jhsph.edu</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Bachmann</surname><given-names>Lucas M</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>lucas.bachmann@usz.ch</email></contrib><contrib id="A3" contrib-type="author"><name><surname>Kleijnen</surname><given-names>Jos</given-names></name><xref ref-type="aff" rid="I3">3</xref><email>jos@systematic-reviews.com</email></contrib><contrib id="A4" contrib-type="author"><name><surname>ter Riet</surname><given-names>Gerben</given-names></name><xref ref-type="aff" rid="I4">4</xref><email>G.terRiet@amc.uva.nl</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Kessels</surname><given-names>Alphons G</given-names></name><xref ref-type="aff" rid="I5">5</xref><email>fons.kessels@mumc.nl</email></contrib></contrib-group><aff id="I1"><label>1</label>Horten Centre for Patient Oriented Research and Knowledge Transfer, University of Zurich, Switzerland</aff><aff id="I2"><label>2</label>Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA</aff><aff id="I3"><label>3</label>Kleijnen Systematic Reviews Ltd, York, UK</aff><aff id="I4"><label>4</label>Academic Medical Center, Dept. General Practice, University of Amsterdam, 1105 AZ Amsterdam, the Netherlands</aff><aff id="I5"><label>5</label>Medical Technology Assessment and Epidemiology, Clinical Epidemiology, Clinical Pharmacy, University Hospital Maastricht, Maastricht, the Netherlands</aff><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>14</day><month>1</month><year>2009</year></pub-date><volume>7</volume><fpage>2</fpage><lpage>2</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1741-7015/7/2"/><history><date date-type="received"><day>11</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>14</day><month>1</month><year>2009</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2009 Puhan et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2009</copyright-year><copyright-holder>Puhan et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>               Puhan               A               Milo                                             mpuhan@jhsph.edu            </dc:author><dc:title>            Inhaled drugs to reduce exacerbations in patients with chronic obstructive pulmonary disease: a network meta-analysis         </dc:title><dc:date>2009</dc:date><dcterms:bibliographicCitation>BMC Medicine 7(1): 2-. (2009)</dcterms:bibliographicCitation><dc:identifier type="sici">1741-7015(2009)7:1&#x0003c;2&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1741-7015</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Most patients with chronic obstructive pulmonary disease (COPD) receive inhaled long-acting bronchodilators and inhaled corticosteroids. Conventional meta-analyses established that these drugs reduce COPD exacerbations when separately compared with placebo. However, there are relatively few head-to-head comparisons and conventional meta-analyses focus on single comparisons rather than on a simultaneous analysis of competing drug regimens that would allow rank ordering of their effectiveness. Therefore we assessed, using a network meta-analytic technique, the relative effectiveness of the common inhaled drug regimes used to reduce exacerbations in patients with COPD.</p></sec><sec sec-type="methods"><title>Methods</title><p>We conducted a systematic review and searched existing systematic reviews and electronic databases for randomized trials of &#x02265; 4 weeks' duration that assessed the effectiveness of inhaled drug regimes on exacerbations in patients with stable COPD. We extracted participants and intervention characteristics from included trials and assessed their methodological quality. For each treatment group we registered the proportion of patients with &#x02265; 1 exacerbation during follow-up. We used treatment-arm based logistic regression analysis to estimate the absolute and relative effects of inhaled drug treatments while preserving randomization within trials.</p></sec><sec><title>Results</title><p>We identified 35 trials enrolling 26,786 patients with COPD of whom 27% had &#x02265; 1 exacerbation. All regimes reduced exacerbations statistically significantly compared with placebo (odds ratios ranging from 0.71 (95% confidence interval [CI] 0.64 to 0.80) for long-acting anticholinergics to 0.78 (95% CI 0.70 to 0.86) for inhaled corticosteroids). Compared with long-acting bronchodilators alone, combined treatment was not more effective (comparison with long-acting beta-agonists: odds ratio 0.93 [95% CI 0.84 to 1.04] and comparison with long-acting anticholinergics: odds ratio 1.02 [95% CI 0.90 to 1.16], respectively). If FEV<sub>1 </sub>was &#x02264; 40% predicted, long-acting anticholinergics, inhaled corticosteroids, and combination treatment reduced exacerbations significantly compared with long-acting beta-agonists alone, but not if FEV<sub>1 </sub>was &#x0003e; 40% predicted. This effect modification was significant for inhaled corticosteroids (<italic>P </italic>= 0.02 for interaction) and combination treatment (<italic>P </italic>= 0.01) but not for long-acting anticholinergics (<italic>P </italic>= 0.46). A limitation of this analysis is its exclusive focus on exacerbations and lack of FEV<sub>1 </sub>data for individual patients.</p></sec><sec><title>Conclusion</title><p>We found no evidence that one single inhaled drug regimen is more effective than another in reducing exacerbations. Inhaled corticosteroids when added to long-acting beta-agonists reduce exacerbations only in patients with COPD with FEV<sub>1 </sub>&#x02264; 40%.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Chronic obstructive pulmonary disease (COPD) has become a leading cause of death worldwide and its management requires an enormous amount of human and financial resources [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B2">2</xref>]. Reduction of exacerbation rates is one of the main treatment goals in COPD management since exacerbations bear heavily on the patient's health-related quality of life and prognosis as well as on COPD-related costs [<xref ref-type="bibr" rid="B3">3</xref>]. Several conventional meta-analyses provided evidence that long-acting beta-agonists, long-acting anticholinergics and inhaled corticosteroids reduce exacerbations in patients with COPD when compared with placebo [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. The conventional meta-analyses are, however, less informative about the comparative effectiveness of long-acting beta-agonists and anticholinergics or about the additional value of inhaled corticosteroids when added to long-acting bronchodilators. The comparative effectiveness is of great interest to physicians because the predominant question in clinical practice is to choose between treatments rather than deciding whether to treat or not to treat [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>].</p><p>Opinions differ about whether a long-acting bronchodilator alone is sufficient or if an inhaled corticosteroid provides additional benefits at least for some patients [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B9">9</xref>,<xref ref-type="bibr" rid="B10">10</xref>]. Any added benefit of corticosteroids, if present, should outweigh the associated risk for adverse effects and their additional costs. Conventional meta-analyses [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>] do not provide enough support to solve this debate because evidence from randomized head-to-head comparisons is often unavailable. Also, conventional meta-analyses cannot provide effect estimates for comparisons of more than two treatments at the same time, so that a ranking of competing treatments is not available. Finally, conventional meta-analyses cannot assess subgroup effects reliably [<xref ref-type="bibr" rid="B13">13</xref>] although such information is very valuable for clinicians. Theoretically, a single very large trial would overcome these three limitations of conventional meta-analysis. However, the sample size would need to be a multiple of that of the recently published TORCH trial [<xref ref-type="bibr" rid="B14">14</xref>] (more than 6000 patients) if subgroup effects were to be investigated.</p><p>Since such a trial is very unlikely to become available, a network meta-analysis or individual patient data meta-analysis can be very informative [<xref ref-type="bibr" rid="B15">15</xref>]. Such pooled analyses unify evidence from all randomized trials while fully preserving randomization [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. Therefore, our aim was to assess the relative effectiveness of competing inhaled drug regimens for the prevention of exacerbations in patients with stable COPD in a pooled analysis of randomized comparisons. In addition, we assessed whether the effectiveness depend on the severity of COPD, treatment duration, or the definition of an exacerbation (event based or symptom based).</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Data sources and selection</title><p>We searched the Cochrane Database of Systematic Reviews (Oxford, United Kingdom, 2007, Issue 2), the Database of Abstracts of Reviews of Effects (last search on November 20<sup>th </sup>2007) and the Health Technology Assessment database (last search November on 20<sup>th </sup>2007) for randomized trials included in existing systematic reviews (see Additional file <xref ref-type="supplementary-material" rid="S1">1</xref> for systematic reviews used to identify relevant studies). We based our searches on existing systematic reviews in order to avoid unnecessary duplication of previous work. The existing systematic reviews used extensive search strategies that included several databases such as Medline, EMBASE, CINAHL and LILACS as well as websites of regulatory bodies. In addition, drug companies were approached for unpublished trials. We complemented these searches by entering all included studies into the 'related articles' function of PubMed (last search for trials on November 20<sup>th</sup>, 2007).</p><p>We included randomized trials without any language restrictions that were &#x02265; 4 weeks in duration, included patients with stable COPD, and assessed the effects of long-acting beta-agonists, long-acting anticholinergics, inhaled corticosteroids, or combination treatment (long-acting beta-agonists plus inhaled corticosteroids) on exacerbations with or without placebo control. We included all trials where the proportion of patients with at least one exacerbation during follow-up was reported. We did not include trials where only the mean number of exacerbations per patient year was reported because meta-analysis of such data is prone to bias without individual patient data [<xref ref-type="bibr" rid="B19">19</xref>].</p><p>We retrieved all full reports of potentially eligible trials. Two reviewers (research fellows with medical doctor degrees and one and three years of research experience, respectively) independently assessed them and determined their inclusion or exclusion. If the two reviewers disagreed even after discussion, a third reviewer (epidemiologist with MD and PhD degree) arbitrated. Out of 56 trials identified initially, we excluded 20 (Figure <xref ref-type="fig" rid="F1">1</xref>, see also Additional file <xref ref-type="supplementary-material" rid="S2">2</xref> for excluded studies). Another trial met the inclusion criteria but it could not be included in the analysis because the treatments (combination of long-acting beta-agonist, long-acting anticholinergic and inhaled corticosteroid versus one or two components), were dissimilar to those in the included trials [<xref ref-type="bibr" rid="B20">20</xref>]. We included the remaining 35 randomized trials in the analysis [<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B21">21</xref>-<xref ref-type="bibr" rid="B54">54</xref>]. One trial [<xref ref-type="bibr" rid="B35">35</xref>] was republished together with another trial [<xref ref-type="bibr" rid="B24">24</xref>]. We considered the data from both trials as published in the second report [<xref ref-type="bibr" rid="B24">24</xref>].</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Study flow from database searches to inclusion oftrials</bold>. 40 trials were excluded after title and abstract screening because they obviously did not fulfill the inclusion criteria (not patients with COPD, patients with unstable COPD, short-acting bronchodilators, treatment duration &#x0003c; 4 weeks, no exacerbations ascertained). Reasons for exclusion for the 20 studies excluded after full text assessment are listed in Additional file <xref ref-type="supplementary-material" rid="S2">2</xref>.</p></caption><graphic xlink:href="1741-7015-7-2-1"/></fig></sec><sec><title>Data extraction</title><p>We focused our analysis on exacerbations. For each trial arm (2 to 4, depending on the trial), one reviewer extracted the number of patients with at least one exacerbation during follow-up and the number of patients with no exacerbation during follow-up (2 &#x000d7; 2, 3 &#x000d7; 2, or 4 &#x000d7; 2 tables). A second and, in case of disagreement, third reviewer, checked the data extraction for correctness. We also recorded whether the studies' definition of exacerbation was event based (physician or emergency room visit, hospital admission) or symptom based (increase of dyspnea, sputum, or cough; for example according to Anthonisen et al [<xref ref-type="bibr" rid="B55">55</xref>]) and recorded the severity of exacerbation according to the Operational Classification of Severity of the European Respiratory and American Thoracic Societies (severe or mild to moderate exacerbation defined as requiring inpatient treatment or outpatient treatment, respectively) [<xref ref-type="bibr" rid="B9">9</xref>]. We recorded the drugs that were evaluated and classified them into the categories of placebo, long-acting beta-agonists (salmeterol, formoterol), long-acting anticholinergics (tiotropium bromide), and inhaled corticosteroids (budesonide, fluticasone, flunisolide, or beclomethasone), or combined treatment with a long-acting beta-agonist and an inhaled corticosteroid. Finally, we recorded treatment duration in weeks, the patient group's mean age, and mean FEV<sub>1</sub>.</p></sec><sec><title>Study reporting quality assessment</title><p>For each trial, two reviewers independently evaluated the quality of reporting for important components of internal validity (Additional file <xref ref-type="supplementary-material" rid="S3">3</xref>). We assessed the method of randomization, concealment of random allocation and whether inclusion criteria were specified in order to judge whether confounding was controlled for by randomization and/or restriction. We recorded blinding of treatment providers and patients to judge the presence of information bias and we recorded whether an intention-to-treat analysis was reported to assess if randomization was maintained throughout the analyses. We resolved discordant scores based on real differences in interpretation through consensus or third party arbitration. We used the quality assessment to judge the validity of the trial results.</p></sec><sec><title>Data synthesis and analysis</title><p>Based on 2 &#x000d7; 2 tables from each study (or 3 &#x000d7; 2 and 4 &#x000d7; 2 tables, respectively), we created as many data entries with respective coding for treatment and exacerbation (yes/no) as there were patients in the respective cell. For example, in the study of Brusasco et al [<xref ref-type="bibr" rid="B24">24</xref>] there were 156 patients in the placebo group with an exacerbation and 244 patients without an exacerbation, resulting in 156 (exacerbation = yes) and 244 (exacerbation = no) data entries for the 400 patients with placebo. For each of these entries we entered the mean age and FEV<sub>1 </sub>as covariates. For a detailed description of creating such a data set, see Additional file <xref ref-type="supplementary-material" rid="S4">4</xref>.</p><p>We performed a logistic regression arm-level analysis with the presence of exacerbation as dependent and the different treatment options as independent variables. We started with placebo treatment as the reference group followed by identical analyses where long-acting beta-agonists, long-acting anticholinergics and inhaled corticosteroids, respectively, served as reference group to which the other treatments were compared. To preserve randomization within each trial, we included a dummy variable for each of the studies. This dummy variable also adjusted for differences in risk profiles and study setup between trials. Second, we conducted stratified analyses to assess whether treatment duration or follow-up, respectively, disease severity (expressed by FEV<sub>1</sub>), or the definition of exacerbation influenced the (relative) treatment effects. We performed separate analyses for trials with a treatment duration of &#x02264; and &#x0003e; 6 months and&#x02264;and &#x0003e; 12 months, for trials with event- or symptom-based exacerbations, and for trials including patients with a mean post-bronchodilator FEV<sub>1 </sub>of &#x02264; and &#x0003e; 40% and 50% predicted (where available). We did not select 35% predicted as cut-off because there was only one trial [<xref ref-type="bibr" rid="B47">47</xref>] with such a low mean FEV<sub>1</sub>. To assess effect modification formally, we tested for interaction by introducing product terms between predictor variables and treatments into the logistic regression analysis. With a random coefficient model, we investigated the presence of any additional variation of the treatment effects due to differences across trials [<xref ref-type="bibr" rid="B56">56</xref>]. All analyses were conducted using STATA (STATA&#x02122; for Windows, version 9, Stata Corp; College Station, TX).</p></sec><sec><title>Role of the funding source</title><p>This work was supported by the Swiss National Science Foundation and The Helmut Horten Foundation. These funding sources did not have any influence on the planning, conduct and reporting of this study.</p></sec></sec><sec><title>Results</title><sec><title>Study characteristics</title><p>Table <xref ref-type="table" rid="T1">1</xref> (parts A-E) shows the characteristics of the 35 trials with 26,786 patients. Median sample size per trial was 545 (interquartile range, 253 to 976). On the patient level, median treatment duration was 25 weeks (interquartile range, 12 to 52), median age was 64 years (interquartile range, 63 to 65), and median FEV<sub>1 </sub>42% predicted (interquartile range, 40 to 46). A total of 26 trials (74%) with 23,245 patients used an event-based definition for exacerbations, and nine trials (26%) with 3541 patients had a symptom-based definition. 7201 patients (27%) suffered from at least one exacerbation. A total of 8312 patients received placebo (32 trials), 6357 received long-acting beta-agonists (21 trials), 4764 received a long-acting anticholinergic (11 trials), 3492 an inhaled corticosteroid (12 trials), and 3861 patients combination treatment (8 trials).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Study characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Part A</bold></td><td></td><td></td><td></td><td></td><td></td></tr></thead><tbody><tr><td align="left"><bold>Study</bold></td><td align="left"><bold>Population</bold></td><td align="left"><bold>Inhaled drug treatment</bold></td><td align="left"><bold>Treatment duration (months)</bold></td><td align="left"><bold>Definition of exacerbation</bold></td><td align="left"><bold>Severity of exacerbation</bold></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Baumgartner et al 2007 [<xref ref-type="bibr" rid="B48">48</xref>]</td><td align="left"><italic>n </italic>= 433 (58% males)<break/>Mean age in years: 63<break/>Mean FEV1: 41% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 42 &#x003bc;g bid<break/><bold>Group 2</bold>: Formoterol 25 &#x003bc;g bid<break/><bold>Group 3</bold>: Placebo</td><td align="left">3</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Beeh et al 2006 [<xref ref-type="bibr" rid="B21">21</xref>]</td><td align="left"><italic>n </italic>= 1639 (76% males)<break/>Mean age in years: 62<break/>Mean FEV1: 45% predicted</td><td align="left"><bold>Group 1</bold>: Tiotropium 18 &#x003bc;g qd<break/><bold>Group 2</bold>: Placebo</td><td align="left">3</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Bourbeau et al 1998 [<xref ref-type="bibr" rid="B22">22</xref>]</td><td align="left"><italic>n </italic>= 79 (66% males)<break/>Mean age in years: 66<break/>Mean FEV1: 43% predicted</td><td align="left"><bold>Group 1</bold>: Budesonide 800 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">6</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Boyd et al 1997[<xref ref-type="bibr" rid="B23">23</xref>]</td><td align="left"><italic>n </italic>= 445 (79% males)<break/>Mean age in years: 62<break/>Mean FEV1: &#x02248;65% predicted (only FEV1 in liters reported)</td><td align="left"><bold>Group 1</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">3.5</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Briggs et al 2005[<xref ref-type="bibr" rid="B49">49</xref>]</td><td align="left"><italic>n </italic>= 653 (66% males)<break/>Mean age in years: 64<break/>Mean FEV1: 38% predicted</td><td align="left"><bold>Group 1</bold>: Tiotropium 18 &#x003bc;g qd<break/><bold>Group 2</bold>: Salmeterol 50 &#x003bc;g bid</td><td align="left">3</td><td align="left">Symptom-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Brusasco et al 2003 [<xref ref-type="bibr" rid="B24">24</xref>,<xref ref-type="bibr" rid="B35">35</xref>]</td><td align="left"><italic>n </italic>= 1207 (76% males)<break/>Mean age in years: 64<break/>Mean FEV1: 38% predicted</td><td align="left"><bold>Group 1</bold>: Tiotropium 18 &#x003bc;g qd<break/><bold>Group 2</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group3</bold>: Placebo</td><td align="left">6</td><td align="left">Symptom-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Burge et al 2000 [<xref ref-type="bibr" rid="B25">25</xref>]</td><td align="left">n = 742 (75% males)<break/>Mean age in years: 64<break/>Mean FEV1: 50% predicted</td><td align="left"><bold>Group 1</bold>: Fluticasone 500 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">36</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Calverley et al 2003 [<xref ref-type="bibr" rid="B26">26</xref>]</td><td align="left"><italic>n </italic>= 1465 (76% males)<break/>Mean age in years: 63<break/>Mean FEV1: 45% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group 2</bold>: Fluticasone 500 &#x003bc;g bid<break/><bold>Group 3</bold>: Salmeterol 50 &#x003bc;g bid + Fluticasone 500 &#x003bc;g bid<break/><bold>Group 4</bold>: Placebo</td><td align="left">12</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>Part B</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Calverley et al 2003 [<xref ref-type="bibr" rid="B27">27</xref>]</td><td align="left"><italic>n </italic>= 1022 (73% males)<break/>Mean age in years: 64<break/>Mean FEV1: 36% predicted</td><td align="left"><bold>Group 1</bold>: Formoterol 9 &#x003bc;g bid<break/><bold>Group 2</bold>: Budesonide 400 &#x003bc;g bid<break/><bold>Group 3</bold>: Formoterol 9 &#x003bc;g bid + Budesonide 320 &#x003bc;g bid<break/><bold>Group 4</bold>: Placebo</td><td align="left">12</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Calverley et al 2003 [<xref ref-type="bibr" rid="B28">28</xref>]</td><td align="left"><italic>n </italic>= 78 (60% males)<break/>Mean age in years: 65<break/>Mean FEV1: 40% predicted</td><td align="left"><bold>Group 1</bold>: Tiotropium 18 &#x003bc;g qd<break/><bold>Group 2</bold>: Placebo</td><td align="left">6</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Calverley et al 2007 [<xref ref-type="bibr" rid="B14">14</xref>]</td><td align="left"><italic>n </italic>= 6112 (76% males)<break/>Mean age in years: 65<break/>Mean FEV1: 44% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group 2</bold>: Fluticasone 500 &#x003bc;g bid<break/><bold>Group 3</bold>: Salmeterol 50 &#x003bc;g bid + Fluticasone 500 &#x003bc;g bid<break/><bold>Group 4</bold>: Placebo</td><td align="left">36</td><td align="left">Event-based</td><td align="left">Severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Campbell et al 2005 [<xref ref-type="bibr" rid="B29">29</xref>]</td><td align="left"><italic>n </italic>= 432 (67% males)<break/>Mean age in years: 60<break/>Mean FEV1: 54% predicted</td><td align="left"><bold>Group 1</bold>: Formoterol 9 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">6</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Casaburi et al 2002 [<xref ref-type="bibr" rid="B50">50</xref>]</td><td align="left"><italic>n </italic>= 921 (65% males)<break/>Mean age in years: 65<break/>Mean FEV1: 36% predicted</td><td align="left"><bold>Group 1</bold>: Tiotropium 18 &#x003bc;g qd<break/><bold>Group 2</bold>: Placebo</td><td align="left">12</td><td align="left">Symptom-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Celli et al 2003 [<xref ref-type="bibr" rid="B30">30</xref>]</td><td align="left"><italic>n </italic>= 824 (70% males)<break/>Mean age in years: 64<break/>Mean FEV1: 42% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">3</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Chapman et al 2002 [<xref ref-type="bibr" rid="B31">31</xref>]</td><td align="left"><italic>n </italic>= 408 (64% males)<break/>Mean age: not reported<break/>Mean FEV1: 45% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">5.5</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Covelli et al 2004 [<xref ref-type="bibr" rid="B32">32</xref>]</td><td align="left"><italic>n </italic>= 196 (66% males)<break/>Mean age in years: 65<break/>Mean FEV1: 40% predicted</td><td align="left"><bold>Group 1</bold>: Tiotropium 18 &#x003bc;g qd<break/><bold>Group 2</bold>: Placebo</td><td align="left">3</td><td align="left">Symptom-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>Part C</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Dahl et al 2001 [<xref ref-type="bibr" rid="B33">33</xref>]</td><td align="left"><italic>n </italic>= 392 (75% males)<break/>Mean age in years: 64<break/>Mean FEV1: 45% predicted</td><td align="left"><bold>Group 1</bold>: Formoterol 24 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">3</td><td align="left">Event-based</td><td align="left">Severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Dusser et al 2006 [<xref ref-type="bibr" rid="B34">34</xref>]</td><td align="left"><italic>n </italic>= 1010 (88% males)<break/>Mean age in years: 65<break/>Mean FEV1: 48% predicted</td><td align="left"><bold>Group 1</bold>: Tiotropium 18 &#x003bc;g qd<break/><bold>Group 2</bold>: Placebo</td><td align="left">12</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Hanania et al 2003 [<xref ref-type="bibr" rid="B51">51</xref>]</td><td align="left"><italic>n </italic>= 540 (63% males)<break/>Mean age in years: 64<break/>Mean FEV1: 42% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group 2</bold>: Fluticasone 250 &#x003bc;g bid<break/><bold>Group 3</bold>: Salmeterol 50 &#x003bc;g bid + Fluticasone 250 &#x003bc;g bid<break/><bold>Group 4</bold>: Placebo</td><td align="left">5.5</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Kardos et al 2007 [<xref ref-type="bibr" rid="B52">52</xref>]</td><td align="left"><italic>n </italic>= 994 (76% males)<break/>Mean age in years: 64<break/>Mean FEV1: 40% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group 2</bold>: Salmeterol 50 &#x003bc;g bid + Fluticasone 500 &#x003bc;g bid</td><td align="left">10</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Littner et al 2000 [<xref ref-type="bibr" rid="B36">36</xref>]</td><td align="left"><italic>n </italic>= 68 (65% males)<break/>Mean age in years: 66<break/>Mean FEV1: 42% predicted</td><td align="left"><bold>Group 1</bold>: Tiotropium 18 &#x003bc;g qd<break/><bold>Group 2</bold>: Placebo</td><td align="left">1</td><td align="left">Symptom-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Mahler et al 1999 [<xref ref-type="bibr" rid="B37">37</xref>]</td><td align="left"><italic>n </italic>= 278 (74% males)<break/>Mean age in years: 63<break/>Mean FEV1: 40% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 42 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">3</td><td align="left">Symptom-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Mahler et al 2002 [<xref ref-type="bibr" rid="B38">38</xref>]</td><td align="left"><italic>n </italic>= 671 (66% males)<break/>Mean age in years: 64<break/>Mean FEV1: 41% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group 2</bold>: Fluticasone 500 &#x003bc;g bid<break/><bold>Group 3</bold>: Salmeterol 50 &#x003bc;g bid + Fluticasone 500 &#x003bc;g bid<break/><bold>Group 4</bold>: Placebo</td><td align="left">5.5</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>Part D</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Niewoehner et al 2005 [<xref ref-type="bibr" rid="B39">39</xref>]</td><td align="left"><italic>n </italic>= 1829 (99% males)<break/>Mean age in years: 68<break/>Mean FEV1: 36% predicted</td><td align="left"><bold>Group 1</bold>: Tiotropium 18 &#x003bc;g qd<break/><bold>Group 2</bold>: Placebo</td><td align="left">6</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Paggiaro et al 1998 [<xref ref-type="bibr" rid="B40">40</xref>]</td><td align="left"><italic>n </italic>= 281 (74% males)<break/>Mean age in years: 63<break/>Mean FEV1: 57% predicted</td><td align="left"><bold>Group 1</bold>: Fluticasone 500 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">12</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Paggiaro et al 2006 [<xref ref-type="bibr" rid="B41">41</xref>]</td><td align="left"><italic>n </italic>= 114 (73% males)<break/>Mean age in years: 66<break/>Mean FEV1: 53% predicted</td><td align="left"><bold>Group 1</bold>: Flunisolide 1 mg bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">6</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Rossi 2002[<xref ref-type="bibr" rid="B42">42</xref>]</td><td align="left"><italic>n </italic>= 434 (84% males)<break/>Mean age in years: 63<break/>Mean FEV1: 47% predicted</td><td align="left"><bold>Group 1</bold>: Formoterol 25 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">3</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Stockley et al 2006 [<xref ref-type="bibr" rid="B43">43</xref>]</td><td align="left"><italic>n </italic>= 634 (76% males)<break/>Mean age in years: 62<break/>Mean FEV1: 46% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">12</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Szafranski et al 2000 [<xref ref-type="bibr" rid="B44">44</xref>]</td><td align="left"><italic>n </italic>= 812 (79% males)<break/>Mean age in years: 64<break/>Mean FEV1: 36% predicted</td><td align="left"><bold>Group 1</bold>: Formoterol 4.5 &#x003bc;g bid<break/><bold>Group 2</bold>: Budesonide 200 &#x003bc;g bid<break/><bold>Group 3</bold>: Formoterol 4.5 &#x003bc;g bid + Budesonide 160 &#x003bc;g bid<break/><bold>Group 4</bold>: Placebo</td><td align="left">12</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Van der Valk et al 2002 [<xref ref-type="bibr" rid="B45">45</xref>]</td><td align="left"><italic>n </italic>= 244 (84% males)<break/>Mean age in years: 64<break/>Mean FEV1: 57% predicted</td><td align="left"><bold>Group 1</bold>: Fluticasone 500 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">5.5</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>Part E</bold></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Van Noord et al 2000 [<xref ref-type="bibr" rid="B46">46</xref>]</td><td align="left"><italic>n </italic>= 92 (88% males)<break/>Mean age in years: 65<break/>Mean FEV1: 41% predicted</td><td align="left"><bold>Group 1</bold>: Salmeterol 50 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">3</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Wadbo et al 2002 [<xref ref-type="bibr" rid="B47">47</xref>]</td><td align="left"><italic>n </italic>= 121 (53% males)<break/>Mean age in years: 64<break/>Mean FEV1: 33% predicted</td><td align="left"><bold>Group 1</bold>: Formoterol 18 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">3</td><td align="left">Symptom-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Wedzicha et al 2008 [<xref ref-type="bibr" rid="B53">53</xref>]</td><td align="left"><italic>n </italic>= 1323 (83% males)<break/>Mean age in years: 64<break/>Mean FEV1: 39% predicted</td><td align="left"><bold>Group 1</bold>: Tiotropium 18 &#x003bc;g qd<break/><bold>Group 2</bold>: Salmeterol 50 &#x003bc;g bid + Fluticasone 500 &#x003bc;g bid</td><td align="left">24</td><td align="left">Event-based</td><td align="left">Moderate and severe</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">Weir et al 1999 [<xref ref-type="bibr" rid="B54">54</xref>]</td><td align="left"><italic>n </italic>= 98 (72% males)<break/>Mean age in years: 66<break/>Mean FEV1: not reported</td><td align="left"><bold>Group 1</bold>: Beclomethasone 750&#x02013;1000 &#x003bc;g bid<break/><bold>Group 2</bold>: Placebo</td><td align="left">5.5</td><td align="left">Symptom-based</td><td align="left">Moderate and severe</td></tr></tbody></table></table-wrap></sec><sec><title>Quality of reporting</title><p>The median number of adequately reported aspects of study quality was 4 out of 6 (interquartile range 3&#x02013;5, Additional file <xref ref-type="supplementary-material" rid="S1">1</xref>). This was largely influenced by the frequent reporting of inclusion criteria and blinding (94.1% of trials). However, the method of randomization (35.3%), concealment of random allocation (29.4%) and an intention to treat analysis (50.0%) were reported less frequently.</p></sec><sec><title>Comparisons of inhaled drug regimes</title><p>All treatments significantly reduced exacerbations when compared with placebo, with odds ratios ranging from 0.71 (95% confidence interval [CI] 0.64 to 0.80) for long-acting anticholinergics to 0.78 (95% CI 0.70 to 0.86) for inhaled corticosteroids (Figure <xref ref-type="fig" rid="F2">2</xref>). Comparing active drugs among each other, we found no significant differences between long-acting beta-agonists, long-acting anticholinergics, inhaled corticosteroids, and combination treatment. In particular, there were no significant differences between long-acting beta-agonists and long-acting anticholinergics (odds ratio, 0.91; 95% CI 0.81 to 1.03), or between combination treatment and long-acting beta-agonists (odds ratio, 0.93; 95% CI 0.84 to 1.04) or long-acting anticholinergics alone (odds ratio 1.02; 95% CI 0.90 to 1.16).</p><fig position="float" id="F2"><label>Figure 2</label><caption><p><bold>All comparisons among inhaled drug regimens</bold>. The forest plots show odds ratios (95% confidence intervals) indicating the odds of at least one exacerbation in patients with a drug treatment from the row as compared with treatment from the corresponding column. For example, the odds ratio of 0.91 (0.81 to 1.03) indicates that long-acting anticholinergics are more effective than long-acting beta-agonists, although not significantly so.</p></caption><graphic xlink:href="1741-7015-7-2-2"/></fig><p>When we analyzed patients with FEV<sub>1 </sub>&#x02264; 40% (<italic>n </italic>= 9,434, mean FEV<sub>1 </sub>= 37% predicted), long-acting anticholinergics (odds ratio 0.83; 95% CI 0.71 to 0.98), inhaled corticosteroids (odds ratio 0.75; 95% CI 0.57 to 1.00), and combination treatment (odds ratio 0.79; 95% CI 0.67 to 0.93) reduced exacerbations significantly compared with long-acting beta-agonists alone (Figure <xref ref-type="fig" rid="F3">3</xref>). In patients with FEV<sub>1 </sub>&#x0003e; 40% predicted (<italic>n </italic>= 17,352, mean FEV<sub>1 </sub>= 46% predicted), there were no differences between treatments. Thus, the difference between point estimates in patients with FEV<sub>1 </sub>&#x02264; or &#x0003e; 40% was small for long-acting anticholinergics (0.09) but larger for inhaled corticosteroids (0.35) and combination treatment (0.26). This effect modification was confirmed when we tested for effect modification formally (<italic>P </italic>= 0.46 for long-acting anticholinergics, <italic>P </italic>= 0.02 for inhaled corticosteroids, and <italic>P </italic>= 0.01 for combination treatment). Effects of long-acting anticholinergics and combination treatment did not differ significantly (odds ratio 0.94; 95% CI 0.80 to 1.11). There was no effect modification when stratified for FEV<sub>1 </sub>&#x02264; or &#x0003e; 50%. In the other stratified analyses (stratified for treatment duration of &#x02264; and &#x0003e; 6 months and &#x02264; and &#x0003e; 12 months as well as for definition of exacerbation), we did not observe any influence of treatment duration or the definition of exacerbations on (relative) treatment effects.</p><fig position="float" id="F3"><label>Figure 3</label><caption><p><bold>Treatment comparisons</bold>. Comparisons of long-acting anticholinergics, inhaled corticosteroids and the combination of long-acting beta-agonists + inhaled corticosteroids with long-acting beta-agonists alone stratified for trials including patients with an FEV<sub>1 </sub>&#x0003e; or &#x02264; 40% predicted.</p></caption><graphic xlink:href="1741-7015-7-2-3"/></fig><p>The random coefficient model showed very similar point estimates and 95% CIs. Compared with the simpler logistic regression model, there was very small extra variability arising from differences of treatment effects across trials (point estimates of interstudy variances range from 10<sup>-6 </sup>to 10<sup>-9</sup>).</p></sec></sec><sec><title>Discussion and conclusion</title><p>Based on 35 trials, our analysis showed that all inhaled drug regimens significantly reduced exacerbations but there were no significant differences between them. Thus, it appears that inhaled corticosteroids provide no additional value in reducing exacerbations when used concurrently with long-acting beta-agonists. However, combination treatment appeared to be more effective than beta-agonists alone in patients with low FEV<sub>1</sub>.</p><p>According to the recently published BOLD study, the prevalence of COPD with GOLD stage II to IV in populations over 40 years of age is around 10%, and approximately 80% of these patients have an FEV<sub>1 </sub>&#x02265; 50% predicted (GOLD stage II) [<xref ref-type="bibr" rid="B57">57</xref>]. For these patients, our study suggests that single treatment with long-acting beta-agonists or long-acting anticholinergics is not only the treatment of choice for symptom control but also for preventing exacerbations. Although common practice is to prescribe inhaled corticosteroids also [<xref ref-type="bibr" rid="B58">58</xref>,<xref ref-type="bibr" rid="B59">59</xref>], our findings suggest that these patients do not need the additional medical therapy to reduce exacerbations.</p><p>In contrast, in patients with low FEV<sub>1 </sub>(below 40% predicted), long-acting anticholinergics appear to be the most attractive choice. They are as effective as combination treatment in reducing exacerbations but offer advantages in terms of costs and adverse effects [<xref ref-type="bibr" rid="B53">53</xref>]. The only head-to-head comparison of a long-acting anticholinergic and combination treatment, the recently published INSPIRE study, identified outcomes in agreement with these findings [<xref ref-type="bibr" rid="B53">53</xref>]. The INSPIRE study also showed no clinically relevant differences in health-related quality of life (&#x0003c; 4 points on St. Georges Respiratory Questionnaire). A significant reduction in 2-year mortality was observed with combination treatment (3%) compared with the long-acting anticholinergic (6%). However, this mortality analysis should be interpreted with caution because a closer look at how death was ascertained in the INSPIRE trials reveals that death was only recorded for patients who did not withdraw from treatment (65.5% with combined treatment and 58.3% with long-acting anticholinergic). Thus, it appears that one third of patients did not enter the mortality analysis. Unfortunately, little evidence is available about the combination of long-acting anticholinergics and inhaled corticosteroids; however, a recent Canadian trial indicated that this combination could be the most effective treatment for reducing exacerbations in patients with low FEV<sub>1 </sub>[<xref ref-type="bibr" rid="B20">20</xref>].</p><p>Exacerbation is not the only outcome that should inform the decision for or against adding inhaled corticosteroids to long-acting bronchodilators. Other outcomes should be considered as well. A recent systematic review found no risk reduction in terms of mortality if an inhaled steroid was added to a long-acting bronchodilator [<xref ref-type="bibr" rid="B11">11</xref>]. Health-related quality of life was statistically significantly better after combined treatment (difference of -1.64 units on St. Georges Respiratory Questionnaire; 95% CI -2.28 to -1) but the effects were well under the threshold representing a minimal important difference (4 units) [<xref ref-type="bibr" rid="B11">11</xref>]. Arguments for treating COPD solely with long-acting beta-agonists are the substantially lower costs and lower risk for adverse effects such as pneumonia, oral candidiasis, or loss of bone density compared with combination treatment [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B14">14</xref>,<xref ref-type="bibr" rid="B53">53</xref>,<xref ref-type="bibr" rid="B60">60</xref>]. Integrating and presenting this complex information about benefits and downsides of inhaled drug treatments is challenging. One approach is to use decision aids that are particularly valuable for value-sensitive decisions where the balance of benefits and downsides is not straightforward. As the decision is, in the case of inhaled drug treatment for COPD, only between two treatment options (bronchodilator(s) versus combined treatment), information about the comparisons with placebo could now be excluded for simplicity, since offering no treatment is not in the best interest of the patient. However, whether patients benefit from such informed decision-making requires testing in additional trials.</p><p>Unlike previous meta-analyses based on comparisons of inhaled drugs with placebo or, in some instances, with another inhaled drug [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B12">12</xref>], we argue that the comparative effectiveness of available treatments are of greater interest to physicians [<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. To provide estimates for this comparative effectiveness, we used a new analytical approach to pool evidence from all available randomized trials. Such analyses may be, in many instances, the only way to estimate comparative treatment effectiveness; head-to-head comparisons are unavailable, and the sample sizes required to detect small differences are unfeasibly large. For comparison of inhaled COPD drugs, for example, thousands of patients are required just for the main comparison, not even accounting for subgroup effects.</p><p>There are other approaches for indirect comparisons [<xref ref-type="bibr" rid="B16">16</xref>-<xref ref-type="bibr" rid="B18">18</xref>]. An early and important contribution emphasized the importance of preserving randomization [<xref ref-type="bibr" rid="B16">16</xref>]. However, that proposed approach only allows for a single head-to-head comparison and not for simultaneous comparison of all treatments under consideration. Two other approaches [<xref ref-type="bibr" rid="B17">17</xref>,<xref ref-type="bibr" rid="B18">18</xref>] are available, but the complexity of their statistical methods may represent a barrier for their application and interpretation [<xref ref-type="bibr" rid="B61">61</xref>]. Our approach is particularly attractive because it is transparent and easily reproducible. The multivariable logistic regression analysis allows for an analysis like that used in any randomized trial while keeping intact the randomization of each trial. The comparisons with placebo showed the same results as those of the meta-analyses of the Clinical Practice Guideline of the American College of Physicians [<xref ref-type="bibr" rid="B6">6</xref>]. When the odds ratios are transformed to relative risks [<xref ref-type="bibr" rid="B62">62</xref>], the effect estimates are identical to those of a conventional meta-analysis.</p><p>A limitation of our study is that we focused on exacerbations and did not consider additional outcomes such as health-related quality of life or mortality. When we planned the current analyses the body of evidence on mortality was too small to provide precise effect estimates, even if pooled. The TORCH trial [<xref ref-type="bibr" rid="B14">14</xref>] published in 2007 was the first trial that was powered to assess the effects of inhaled drugs on mortality, but even this very large trial turned out to be too small. Therefore, we decided to postpone analyses on mortality to a point in time where more data would become available. Another limitation is that we performed only a few stratified analyses. For physicians, knowing more about profile-specific effect estimates would be very useful. For example, more detailed information about risk factors for exacerbations, such as previous exacerbations, would enhance understanding about who benefits from the addition of inhaled corticosteroids. Single trials are unlikely to provide such information because of the very large sample sizes they would require for sufficient power to detect effect modification. Individual patient data meta-analysis and pooled analyses may solve this problem to some extent. However, reporting of such patient characteristics is highly variable, and retrieval of individual patient data from primary studies is challenging [<xref ref-type="bibr" rid="B63">63</xref>].</p><p>A limitation of any approach to pool data on exacerbations is that (relative) treatment effects can only be estimated adequately based on the proportion of patients with at least one exacerbation. Analysis of exacerbation rates expressed as mean exacerbation rates per person-year would offer a more comprehensive use of the data and would be less dependent on the length of follow-up. However, such data cannot be pooled adequately without having access to adequate and fully reported analyses that took within- and between-patient variability in exacerbations into account. But as Suissa points out, most trials are not analyzed and reported adequately[<xref ref-type="bibr" rid="B19">19</xref>]. Ideally, an individual patient data meta-analysis would be conducted but it is very challenging to convince investigators of all relevant trials to share their data [<xref ref-type="bibr" rid="B63">63</xref>]. The advantage of using the proportion of patients with at least one exacerbation is the limited influence of few patients with many exacerbations on the results. Also, physicians may be more familiar with this format and respective estimates for treatment effects such as odds ratios or relative risks than with mean differences in exacerbation rates. However, there is little evidence on how effect estimates should be presented in order to facilitate the transfer from research into practice.</p><p>A common problem of systematic reviews in COPD is poor reporting of clinical and spirometric characteristics of patients enrolled in included trials. It is sometimes difficult to judge whether all patients had COPD, or if some patients had other lung disease such as asthma. Also, there is often no separate reporting for moderate and severe exacerbations, although it would be informative to estimate the effects of inhaled steroids stratified for the severity of exacerbations. COPD is a heterogeneous disease and it is important that future studies provide more information about their patients, including clinical characteristics, lung function data and also information on co-treatments.</p><p>The results of our study may support physicians in selecting inhaled drug treatments for patients with COPD. In general, long-acting beta-agonists or anticholinergics appear to be the treatment of choice to reduce exacerbation rates. Adding an inhaled corticosteroid does not provide additional protection from exacerbations. In patients with low FEV<sub>1</sub>, combination treatment and long-acting anticholinergics should be favored because they reduce the risk for exacerbations more than single treatment with a long-acting beta-agonist. Our analyses, together with the existing meta-analyses that considered additional outcomes, inform patients and physicians to balance the benefits and downsides of different inhaled drug treatments for COPD.</p></sec><sec><title>Competing interests</title><p>None of the authors has any competing interests related to the content of this paper. Dr. Kleijnen received restricted research grants from Pfizer Ltd.</p></sec><sec><title>Authors' contributions</title><p>All authors had full access to all of the data in the study. MAP takes responsibility for the integrity of the data and accuracy of the data analysis. MAP, LMB, JK, and AGK undertook Study concept and design. MAP, LMB and AGK were responsible for data acquisition. MAP, LMB, JK, GtR and AGK performed Analysis and interpretation of data. MAP, LMB and AGK drafted the manuscript. JK and GtR undertook critical revision of the manuscript for important intellectual content. MAP, LMB, GtR and AGK performed the statistical analysis. JK and AGK supervised the study. All authors have read and approved the final manuscript.</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1741-7015/7/2/prepub"/></p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="S1"><caption><title>Additional file 1</title><p><bold>Appendix 1.</bold> Existing systematic reviews used for identification of articles.</p></caption><media xlink:href="1741-7015-7-2-S1.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S2"><caption><title>Additional file 2</title><p><bold>Appendix 2.</bold> Excluded studies.</p></caption><media xlink:href="1741-7015-7-2-S2.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S3"><caption><title>Additional file 3</title><p><bold>Appendix 3.</bold> Quality assessment.</p></caption><media xlink:href="1741-7015-7-2-S3.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="S4"><caption><title>Additional file 4</title><p><bold>Appendix 4.</bold> Approach to create new data set with n data entries where n is the total number of included patients.</p></caption><media xlink:href="1741-7015-7-2-S4.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for file</p></caption></media></supplementary-material></sec></body><back><ack><sec><title>Acknowledgements</title><p>Dr Milo A Puhan's (grant no. 3233B0/115216/1) and Dr Lucas M Bachmann's work (grants no. 3233B0-103182 and 3200B0-103183) was supported by the Swiss National Science Foundation. The Helmut Horten Foundation supported Dr Milo A Puhan, Dr M Bachmann and Dr G ter Riet.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barnes</surname><given-names>PJ</given-names></name></person-group><article-title>Chronic obstructive pulmonary disease: a growing but neglected global epidemic</article-title><source>PLoS Med</source><year>2007</year><volume>4</volume><fpage>e112</fpage><pub-id pub-id-type="pmid">17503959</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lopez</surname><given-names>AD</given-names></name><name><surname>Shibuya</surname><given-names>K</given-names></name><name><surname>Rao</surname><given-names>C</given-names></name><name><surname>Mathers</surname><given-names>CD</given-names></name><name><surname>Hansell</surname><given-names>AL</given-names></name><name><surname>Held</surname><given-names>LS</given-names></name><name><surname>Schmid</surname><given-names>V</given-names></name><name><surname>Buist</surname><given-names>S</given-names></name></person-group><article-title>Chronic obstructive pulmonary disease: current burden and future projections</article-title><source>Eur Respir J</source><year>2006</year><volume>27</volume><fpage>397</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">16452599</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wedzicha</surname><given-names>JA</given-names></name><name><surname>Seemungal</surname><given-names>TA</given-names></name></person-group><article-title>COPD exacerbations: defining their cause and prevention</article-title><source>Lancet</source><year>2007</year><volume>370</volume><fpage>786</fpage><lpage>796</lpage><pub-id pub-id-type="pmid">17765528</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nannini</surname><given-names>L</given-names></name><name><surname>Cates</surname><given-names>C</given-names></name><name><surname>Lasserson</surname><given-names>T</given-names></name><name><surname>Poole</surname><given-names>P</given-names></name></person-group><article-title>Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>4</volume><fpage>CD003794</fpage><pub-id pub-id-type="pmid">17943798</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>IA</given-names></name><name><surname>Fong</surname><given-names>KM</given-names></name><name><surname>Sim</surname><given-names>EH</given-names></name><name><surname>Black</surname><given-names>PN</given-names></name><name><surname>Lasserson</surname><given-names>TJ</given-names></name></person-group><article-title>Inhaled corticosteroids for stable chronic obstructive pulmonary disease</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>2</volume><fpage>CD002991</fpage><pub-id pub-id-type="pmid">17443520</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilt</surname><given-names>TJ</given-names></name><name><surname>Niewoehner</surname><given-names>D</given-names></name><name><surname>Macdonald</surname><given-names>R</given-names></name><name><surname>Kane</surname><given-names>RL</given-names></name></person-group><article-title>Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline</article-title><source>Ann Intern Med</source><year>2007</year><volume>147</volume><fpage>639</fpage><lpage>653</lpage><pub-id pub-id-type="pmid">17975187</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tunis</surname><given-names>SR</given-names></name><name><surname>Stryer</surname><given-names>DB</given-names></name><name><surname>Clancy</surname><given-names>CM</given-names></name></person-group><article-title>Practical clinical trials: increasing the value of clinical research for decision making in clinical and health policy</article-title><source>Jama</source><year>2003</year><volume>290</volume><fpage>1624</fpage><lpage>1632</lpage><pub-id pub-id-type="pmid">14506122</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rothman</surname><given-names>KJ</given-names></name><name><surname>Michels</surname><given-names>KB</given-names></name></person-group><article-title>The continuing unethical use of placebo controls</article-title><source>New Engl J Med</source><year>1994</year><volume>331</volume><fpage>394</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">8028622</pub-id></citation></ref><ref id="B9"><citation citation-type="other"><person-group person-group-type="author"><collab>American Thoracic Society and European Respiratory Society</collab></person-group><article-title>Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease</article-title><year>2007</year><ext-link ext-link-type="uri" xlink:href="http://www.ers-education.org/pages/default.aspx?id=725"/></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suissa</surname><given-names>S</given-names></name><name><surname>McGhan</surname><given-names>R</given-names></name><name><surname>Niewoehner</surname><given-names>D</given-names></name><name><surname>Make</surname><given-names>B</given-names></name></person-group><article-title>Inhaled corticosteroids in chronic obstructive pulmonary disease</article-title><source>Proc Am Thorac Soc</source><year>2007</year><volume>4</volume><fpage>535</fpage><lpage>542</lpage><pub-id pub-id-type="pmid">17878466</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nannini</surname><given-names>L</given-names></name><name><surname>Cates</surname><given-names>C</given-names></name><name><surname>Lasserson</surname><given-names>T</given-names></name><name><surname>Poole</surname><given-names>P</given-names></name></person-group><article-title>Combined corticosteroid and long-acting beta-agonist in one inhaler versus long-acting beta-agonists for chronic obstructive pulmonary disease</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>4</volume><fpage>CD006829</fpage><pub-id pub-id-type="pmid">17943918</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nannini</surname><given-names>L</given-names></name><name><surname>Cates</surname><given-names>C</given-names></name><name><surname>Lasserson</surname><given-names>T</given-names></name><name><surname>Poole</surname><given-names>P</given-names></name></person-group><article-title>Combined corticosteroid and long-acting beta-agonist in one inhaler versus inhaled steroids for chronic obstructive pulmonary disease</article-title><source>Cochrane Database Syst Rev</source><year>2007</year><volume>4</volume><fpage>CD006826</fpage><pub-id pub-id-type="pmid">17943917</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Berlin</surname><given-names>JA</given-names></name><name><surname>Santanna</surname><given-names>J</given-names></name><name><surname>Schmid</surname><given-names>CH</given-names></name><name><surname>Szczech</surname><given-names>LA</given-names></name><name><surname>Feldman</surname><given-names>HI</given-names></name></person-group><article-title>Individual patient-versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head</article-title><source>Stat Med</source><year>2002</year><volume>21</volume><fpage>371</fpage><lpage>387</lpage><pub-id pub-id-type="pmid">11813224</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Ferguson</surname><given-names>GT</given-names></name><name><surname>Jenkins</surname><given-names>C</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Yates</surname><given-names>JC</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name></person-group><article-title>Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease</article-title><source>New Engl J Med</source><year>2007</year><volume>356</volume><fpage>775</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">17314337</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caldwell</surname><given-names>DM</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name></person-group><article-title>Simultaneous comparison of multiple treatments: combining direct and indirect evidence</article-title><source>BMJ</source><year>2005</year><volume>331</volume><fpage>897</fpage><lpage>900</lpage><pub-id pub-id-type="pmid">16223826</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bucher</surname><given-names>HC</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Griffith</surname><given-names>LE</given-names></name><name><surname>Walter</surname><given-names>SD</given-names></name></person-group><article-title>The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials</article-title><source>J Clin Epidemiol</source><year>1997</year><volume>50</volume><fpage>683</fpage><lpage>691</lpage><pub-id pub-id-type="pmid">9250266</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name></person-group><article-title>Combination of direct and indirect evidence in mixed treatment comparisons</article-title><source>Stat Med</source><year>2004</year><volume>23</volume><fpage>3105</fpage><lpage>3124</lpage><pub-id pub-id-type="pmid">15449338</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lumley</surname><given-names>T</given-names></name></person-group><article-title>Network meta-analysis for indirect treatment comparisons</article-title><source>Stat Med</source><year>2002</year><volume>21</volume><fpage>2313</fpage><lpage>2324</lpage><pub-id pub-id-type="pmid">12210616</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suissa</surname><given-names>S</given-names></name></person-group><article-title>Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2006</year><volume>173</volume><fpage>842</fpage><lpage>846</lpage><pub-id pub-id-type="pmid">16439716</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aaron</surname><given-names>SD</given-names></name><name><surname>Vandemheen</surname><given-names>KL</given-names></name><name><surname>Fergusson</surname><given-names>D</given-names></name><name><surname>Maltais</surname><given-names>F</given-names></name><name><surname>Bourbeau</surname><given-names>J</given-names></name><name><surname>Goldstein</surname><given-names>R</given-names></name><name><surname>Balter</surname><given-names>M</given-names></name><name><surname>O'Donnell</surname><given-names>D</given-names></name><name><surname>McIvor</surname><given-names>A</given-names></name><name><surname>Sharma</surname><given-names>S</given-names></name><name><surname>Bishop</surname><given-names>G</given-names></name><name><surname>Anthony</surname><given-names>J</given-names></name><name><surname>Cowie</surname><given-names>R</given-names></name><name><surname>Field</surname><given-names>S</given-names></name><name><surname>Hirsch</surname><given-names>A</given-names></name><name><surname>Hernandez</surname><given-names>P</given-names></name><name><surname>Rivington</surname><given-names>R</given-names></name><name><surname>Road</surname><given-names>J</given-names></name><name><surname>Hoffstein</surname><given-names>V</given-names></name><name><surname>Hodder</surname><given-names>R</given-names></name><name><surname>Marciniuk</surname><given-names>D</given-names></name><name><surname>McCormack</surname><given-names>D</given-names></name><name><surname>Fox</surname><given-names>G</given-names></name><name><surname>Cox</surname><given-names>G</given-names></name><name><surname>Prins</surname><given-names>HB</given-names></name><name><surname>Ford</surname><given-names>G</given-names></name><name><surname>Bleskie</surname><given-names>D</given-names></name><name><surname>Doucette</surname><given-names>S</given-names></name><name><surname>Mayers</surname><given-names>I</given-names></name><name><surname>Chapman</surname><given-names>K</given-names></name><name><surname>Zamel</surname><given-names>N</given-names></name><name><surname>FitzGerald</surname><given-names>M</given-names></name><collab>Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium</collab></person-group><article-title>Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial</article-title><source>Ann Intern Med</source><year>2007</year><volume>146</volume><fpage>545</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">17310045</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Beeh</surname><given-names>KM</given-names></name><name><surname>Beier</surname><given-names>J</given-names></name><name><surname>Buhl</surname><given-names>R</given-names></name><name><surname>Stark-Lorenzen</surname><given-names>P</given-names></name><name><surname>Gerken</surname><given-names>F</given-names></name><name><surname>Metzdorf</surname><given-names>N</given-names></name></person-group><article-title>Efficacy of tiotropium bromide (Spiriva) in patients with chronic-obstructive pulmonary disease (COPD) of different severities</article-title><source>Pneumologie</source><year>2006</year><fpage>341</fpage><lpage>346</lpage><pub-id pub-id-type="pmid">16761228</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bourbeau</surname><given-names>J</given-names></name><name><surname>Rouleau</surname><given-names>MY</given-names></name><name><surname>Boucher</surname><given-names>S</given-names></name></person-group><article-title>Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>1998</year><volume>53</volume><fpage>477</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">9713447</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boyd</surname><given-names>G</given-names></name><name><surname>Morice</surname><given-names>AH</given-names></name><name><surname>Pounsford</surname><given-names>JC</given-names></name><name><surname>Siebert</surname><given-names>M</given-names></name><name><surname>Peslis</surname><given-names>N</given-names></name><name><surname>Crawford</surname><given-names>C</given-names></name></person-group><article-title>An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)</article-title><source>Eur Respir J</source><year>1997</year><volume>10</volume><fpage>815</fpage><lpage>821</lpage><pub-id pub-id-type="pmid">9150318</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brusasco</surname><given-names>V</given-names></name><name><surname>Hodder</surname><given-names>R</given-names></name><name><surname>Miravitlles</surname><given-names>M</given-names></name><name><surname>Korducki</surname><given-names>L</given-names></name><name><surname>Towse</surname><given-names>L</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name></person-group><article-title>Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD</article-title><source>Thorax</source><year>2003</year><volume>58</volume><fpage>399</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">12728159</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Burge</surname><given-names>PS</given-names></name><name><surname>Calverley</surname><given-names>PMA</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Spencer</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>JA</given-names></name><name><surname>Maslen</surname><given-names>TK</given-names></name></person-group><article-title>Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial</article-title><source>BMJ</source><year>2000</year><volume>320</volume><fpage>1297</fpage><lpage>1303</lpage><pub-id pub-id-type="pmid">10807619</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>P</given-names></name><name><surname>Pauwels</surname><given-names>R</given-names></name><name><surname>Vestbo</surname><given-names>J</given-names></name><name><surname>Jones</surname><given-names>P</given-names></name><name><surname>Pride</surname><given-names>N</given-names></name><name><surname>Gulsvik</surname><given-names>A</given-names></name><name><surname>Anderson</surname><given-names>J</given-names></name><name><surname>Maden</surname><given-names>C</given-names></name></person-group><article-title>Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial</article-title><source>Lancet</source><year>2003</year><volume>361</volume><fpage>449</fpage><lpage>456</lpage><pub-id pub-id-type="pmid">12583942</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Boonsawat</surname><given-names>W</given-names></name><name><surname>Cseke</surname><given-names>Z</given-names></name><name><surname>Zhong</surname><given-names>N</given-names></name><name><surname>Peterson</surname><given-names>S</given-names></name><name><surname>Olsson</surname><given-names>H</given-names></name></person-group><article-title>Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2003</year><volume>22</volume><fpage>912</fpage><lpage>919</lpage><pub-id pub-id-type="pmid">14680078</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Towse</surname><given-names>L</given-names></name><name><surname>van</surname><given-names>NJ</given-names></name><name><surname>Witek</surname><given-names>TJ</given-names></name><name><surname>Kelsen</surname><given-names>S</given-names></name></person-group><article-title>Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease</article-title><source>Thorax</source><year>2003</year><volume>58</volume><fpage>855</fpage><lpage>860</lpage><pub-id pub-id-type="pmid">14514937</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Campbell</surname><given-names>M</given-names></name><name><surname>Eliraz</surname><given-names>A</given-names></name><name><surname>Johansson</surname><given-names>G</given-names></name><name><surname>Tornling</surname><given-names>G</given-names></name><name><surname>Nihlen</surname><given-names>U</given-names></name><name><surname>Bengtsson</surname><given-names>T</given-names></name><name><surname>Rabe</surname><given-names>KF</given-names></name></person-group><article-title>Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease</article-title><source>Respir Med</source><year>2005</year><volume>99</volume><fpage>1511</fpage><lpage>1520</lpage><pub-id pub-id-type="pmid">16199148</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Celli</surname><given-names>B</given-names></name><name><surname>Halpin</surname><given-names>D</given-names></name><name><surname>Hepburn</surname><given-names>R</given-names></name><name><surname>Byrne</surname><given-names>N</given-names></name><name><surname>Keating</surname><given-names>ET</given-names></name><name><surname>Goldman</surname><given-names>M</given-names></name></person-group><article-title>Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS)</article-title><source>Respir Med</source><year>2003</year><volume>97</volume><fpage>S35</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">12564609</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapman</surname><given-names>KR</given-names></name><name><surname>Arvidsson</surname><given-names>P</given-names></name><name><surname>Chuchalin</surname><given-names>AG</given-names></name><name><surname>Dhillon</surname><given-names>DP</given-names></name><name><surname>Faurschou</surname><given-names>P</given-names></name><name><surname>Goldstein</surname><given-names>RS</given-names></name><name><surname>Kuipers</surname><given-names>AF</given-names></name><collab>International study group</collab></person-group><article-title>The addition of salmeterol 50 mug bid to anticholinergic treatment in patients with COPD: A randomized, placebo controlled trial</article-title><source>Can Respir J</source><year>2002</year><volume>3</volume><fpage>178</fpage><lpage>185</lpage><pub-id pub-id-type="pmid">12068339</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Covelli</surname><given-names>H</given-names></name><name><surname>Bhattacharya</surname><given-names>S</given-names></name><name><surname>Cassino</surname><given-names>C</given-names></name><name><surname>Conoscenti</surname><given-names>C</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name></person-group><article-title>Absence of electrocardiographic findings and improved function with once-daily tiotropium in patients with chronic obstructive pulmonary disease</article-title><source>Pharmacotherapy</source><year>2005</year><volume>25</volume><fpage>1708</fpage><lpage>1718</lpage><pub-id pub-id-type="pmid">16305289</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>R</given-names></name><name><surname>Greefhorst</surname><given-names>LA</given-names></name><name><surname>Nowak</surname><given-names>D</given-names></name><name><surname>Nonikov</surname><given-names>V</given-names></name><name><surname>Byrne</surname><given-names>AM</given-names></name><name><surname>Thomson</surname><given-names>MH</given-names></name><name><surname>Till</surname><given-names>D</given-names></name><name><surname>Della</surname><given-names>CG</given-names></name><collab>Formoterol in Chronic Obstructive Pulmonary D</collab></person-group><article-title>Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2001</year><volume>164</volume><fpage>778</fpage><lpage>784</lpage><pub-id pub-id-type="pmid">11549532</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dusser</surname><given-names>D</given-names></name><name><surname>Bravo</surname><given-names>M-L</given-names></name><name><surname>Iacono</surname><given-names>P</given-names></name><collab>on behalf the MISTRAL study group</collab></person-group><article-title>The effect of tiotropium on exacerbations and airflow in patients with COPD</article-title><source>Eur Respir J</source><year>2006</year><volume>27</volume><fpage>547</fpage><lpage>555</lpage><pub-id pub-id-type="pmid">16507855</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Donohue</surname><given-names>JF</given-names></name><name><surname>Van Noord</surname><given-names>JA</given-names></name><name><surname>Bateman</surname><given-names>ED</given-names></name><name><surname>Langley</surname><given-names>SJ</given-names></name><name><surname>Lee</surname><given-names>A</given-names></name><name><surname>Witek</surname><given-names>TJ</given-names><suffix>Jr</suffix></name><name><surname>Kesten</surname><given-names>S</given-names></name><name><surname>Towse</surname><given-names>L</given-names></name></person-group><article-title>A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol</article-title><source>Chest</source><year>2002</year><volume>1</volume><fpage>47</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">12114338</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Littner</surname><given-names>MR</given-names></name><name><surname>Ilowite</surname><given-names>JS</given-names></name><name><surname>Tashkin</surname><given-names>DP</given-names></name><name><surname>Friedman</surname><given-names>M</given-names></name><name><surname>Serby</surname><given-names>CW</given-names></name><name><surname>Menjoge</surname><given-names>SS</given-names></name><name><surname>Witek</surname><given-names>TJ</given-names><suffix>Jr</suffix></name></person-group><article-title>Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2000</year><volume>161</volume><fpage>1136</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">10764302</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Donohue</surname><given-names>JF</given-names></name><name><surname>Barbee</surname><given-names>RA</given-names></name><name><surname>Goldman</surname><given-names>MD</given-names></name><name><surname>Gross</surname><given-names>NJ</given-names></name><name><surname>Wisniewski</surname><given-names>ME</given-names></name><name><surname>Yancey</surname><given-names>SW</given-names></name><name><surname>Zakes</surname><given-names>BA</given-names></name><name><surname>Rickard</surname><given-names>KA</given-names></name><name><surname>Anderson</surname><given-names>WH</given-names></name></person-group><article-title>Efficacy of salmeterol xinafoate in the treatment of COPD</article-title><source>Chest</source><year>1999</year><volume>115</volume><fpage>957</fpage><lpage>965</lpage><pub-id pub-id-type="pmid">10208192</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Wire</surname><given-names>P</given-names></name><name><surname>Horstman</surname><given-names>D</given-names></name><name><surname>Chang</surname><given-names>C</given-names></name><name><surname>Yates</surname><given-names>J</given-names></name><name><surname>Fischer</surname><given-names>T</given-names></name><name><surname>Shah</surname><given-names>T</given-names></name></person-group><article-title>Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><fpage>1084</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">12379552</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niewoehner</surname><given-names>DE</given-names></name><name><surname>Rice</surname><given-names>K</given-names></name><name><surname>Cote</surname><given-names>C</given-names></name><name><surname>Paulson</surname><given-names>D</given-names></name><name><surname>Cooper</surname><given-names>JA</given-names><suffix>Jr</suffix></name><name><surname>Korducki</surname><given-names>L</given-names></name><name><surname>Cassino</surname><given-names>C</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name></person-group><article-title>Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial</article-title><source>Ann Intern Med</source><year>2005</year><volume>143</volume><fpage>317</fpage><lpage>326</lpage><pub-id pub-id-type="pmid">16144890</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paggiaro</surname><given-names>PL</given-names></name><name><surname>Dahle</surname><given-names>R</given-names></name><name><surname>Bakran</surname><given-names>I</given-names></name><name><surname>Frith</surname><given-names>L</given-names></name><name><surname>Hollingworth</surname><given-names>K</given-names></name><name><surname>Efthimiou</surname><given-names>J</given-names></name></person-group><article-title>Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructuve pulmonary disease</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>773</fpage><lpage>780</lpage><pub-id pub-id-type="pmid">9519948</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Paggiaro</surname><given-names>PL</given-names></name><name><surname>Vagaggini</surname><given-names>B</given-names></name><name><surname>Di</surname><given-names>FA</given-names></name><name><surname>Zingoni</surname><given-names>M</given-names></name><name><surname>Fano</surname><given-names>M</given-names></name><name><surname>Biraghi</surname><given-names>M</given-names></name></person-group><article-title>Efficacy of nebulized flunisolide combined with salbutamol and ipratropium bromide in stable patients with moderate-to-severe chronic obstructive pulmonary disease</article-title><source>Respiration</source><year>2006</year><volume>73</volume><fpage>603</fpage><lpage>609</lpage><pub-id pub-id-type="pmid">16293958</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Kristufek</surname><given-names>P</given-names></name><name><surname>Levine</surname><given-names>BE</given-names></name><name><surname>Thomson</surname><given-names>MH</given-names></name><name><surname>Till</surname><given-names>D</given-names></name><name><surname>Kottakis</surname><given-names>J</given-names></name><name><surname>Della</surname><given-names>CG</given-names></name></person-group><article-title>Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD</article-title><source>Chest</source><year>2002</year><volume>121</volume><fpage>1058</fpage><lpage>1069</lpage><pub-id pub-id-type="pmid">11948033</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stockley</surname><given-names>RA</given-names></name><name><surname>Chopra</surname><given-names>N</given-names></name><name><surname>Rice</surname><given-names>L</given-names></name></person-group><article-title>Addition of salmeterol to existing treatment in patients with COPD: a 12 month study</article-title><source>Thorax</source><year>2006</year><volume>61</volume><fpage>122</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">16443706</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szafranski</surname><given-names>W</given-names></name><name><surname>Cukier</surname><given-names>A</given-names></name><name><surname>Ramirez</surname><given-names>A</given-names></name><name><surname>Menga</surname><given-names>G</given-names></name><name><surname>Sansores</surname><given-names>R</given-names></name><name><surname>Nahabedian</surname><given-names>S</given-names></name><name><surname>Peterson</surname><given-names>S</given-names></name><name><surname>Olsson</surname><given-names>H</given-names></name></person-group><article-title>Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2003</year><volume>21</volume><fpage>74</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">12570112</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>van der Valk</surname><given-names/></name><name><surname>Monninkhof</surname><given-names>E</given-names></name><name><surname>van der</surname><given-names>PJ</given-names></name><name><surname>Zielhuis</surname><given-names>G</given-names></name><name><surname>van</surname><given-names>HC</given-names></name></person-group><article-title>Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study</article-title><source>Am J Respir Crit Care Med</source><year>2002</year><volume>166</volume><fpage>1358</fpage><lpage>1363</lpage><pub-id pub-id-type="pmid">12406823</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Van Noord</surname><given-names>JA</given-names></name><name><surname>De Munck</surname><given-names>DRAJ</given-names></name><name><surname>Bantje</surname><given-names>T</given-names></name><name><surname>Hop</surname><given-names>WCJ</given-names></name><name><surname>Akveld</surname><given-names>MLM</given-names></name><name><surname>Bommer</surname><given-names>AM</given-names></name></person-group><article-title>Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium</article-title><source>Eur Respir J</source><year>2000</year><volume>15</volume><fpage>878</fpage><lpage>885</lpage><pub-id pub-id-type="pmid">10853852</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wadbo</surname><given-names>M</given-names></name><name><surname>Lofdahl</surname><given-names>CG</given-names></name><name><surname>Larsson</surname><given-names>K</given-names></name><name><surname>Skoogh</surname><given-names>BE</given-names></name><name><surname>Tornling</surname><given-names>G</given-names></name><name><surname>Arwestrom</surname><given-names>E</given-names></name><name><surname>Bengtsson</surname><given-names>T</given-names></name><name><surname>Strom</surname><given-names>K</given-names></name><collab>Swedish Society of Respiratory Medicine</collab></person-group><article-title>Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study</article-title><source>Eur Respir J</source><year>2002</year><volume>20</volume><fpage>1138</fpage><lpage>1146</lpage><pub-id pub-id-type="pmid">12449166</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baumgartner</surname><given-names>RA</given-names></name><name><surname>Hanania</surname><given-names>NA</given-names></name><name><surname>Calhoun</surname><given-names>WJ</given-names></name><name><surname>Sahn</surname><given-names>SA</given-names></name><name><surname>Sciarappa</surname><given-names>K</given-names></name><name><surname>Hanrahan</surname><given-names>JP</given-names></name></person-group><article-title>Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial</article-title><source>Clin Ther</source><year>2007</year><volume>29</volume><fpage>261</fpage><lpage>278</lpage><pub-id pub-id-type="pmid">17472819</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Briggs</surname><given-names>DD</given-names><suffix>Jr</suffix></name><name><surname>Covelli</surname><given-names>H</given-names></name><name><surname>Lapidus</surname><given-names>R</given-names></name><name><surname>Bhattycharya</surname><given-names>S</given-names></name><name><surname>Kesten</surname><given-names>S</given-names></name><name><surname>Cassino</surname><given-names>C</given-names></name></person-group><article-title>Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD</article-title><source>Pulm Pharmacol Ther</source><year>2005</year><volume>18</volume><fpage>397</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">16179215</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Casaburi</surname><given-names>R</given-names></name><name><surname>Mahler</surname><given-names>DA</given-names></name><name><surname>Jones</surname><given-names>PW</given-names></name><name><surname>Wanner</surname><given-names>A</given-names></name><name><surname>San</surname><given-names>PG</given-names></name><name><surname>ZuWallack</surname><given-names>RL</given-names></name><name><surname>Menjoge</surname><given-names>SS</given-names></name><name><surname>Serby</surname><given-names>CW</given-names></name><name><surname>Witek</surname><given-names>T</given-names><suffix>Jr</suffix></name></person-group><article-title>A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease</article-title><source>Eur Respir J</source><year>2002</year><volume>19</volume><fpage>217</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">11866001</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanania</surname><given-names>NA</given-names></name><name><surname>Darken</surname><given-names>P</given-names></name><name><surname>Horstman</surname><given-names>D</given-names></name><name><surname>Reisner</surname><given-names>C</given-names></name><name><surname>Lee</surname><given-names>B</given-names></name><name><surname>Davis</surname><given-names>S</given-names></name><name><surname>Shah</surname><given-names>T</given-names></name></person-group><article-title>The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD</article-title><source>Chest</source><year>2003</year><volume>124</volume><fpage>834</fpage><lpage>843</lpage><pub-id pub-id-type="pmid">12970006</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kardos</surname><given-names>P</given-names></name><name><surname>Wencker</surname><given-names>M</given-names></name><name><surname>Glaab</surname><given-names>T</given-names></name><name><surname>Vogelmeier</surname><given-names>C</given-names></name></person-group><article-title>Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease</article-title><source>Am J Respir Crit Care Med</source><year>2007</year><volume>175</volume><fpage>144</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">17053207</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wedzicha</surname><given-names>JA</given-names></name><name><surname>Calverley</surname><given-names>PM</given-names></name><name><surname>Seemungal</surname><given-names>TA</given-names></name><name><surname>Hagan</surname><given-names>G</given-names></name><name><surname>Ansari</surname><given-names>Z</given-names></name><name><surname>Stockley</surname><given-names>RA</given-names></name></person-group><article-title>The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide</article-title><source>Am J Respir Crit Care Med</source><year>2008</year><volume>177</volume><fpage>19</fpage><lpage>26</lpage><pub-id pub-id-type="pmid">17916806</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weir</surname><given-names>DC</given-names></name><name><surname>Bale</surname><given-names>GA</given-names></name><name><surname>Bright</surname><given-names>P</given-names></name><name><surname>Sherwood Burge</surname><given-names>P</given-names></name></person-group><article-title>A double-blind placebo-controlled study of the effect of inhaled beclomethasone dipropionate for 2 years in patients with nonasthmatic chronic obstructive pulmonary disease</article-title><source>Clin Exp Allergy</source><year>1999</year><volume>29</volume><fpage>125</fpage><lpage>128</lpage><pub-id pub-id-type="pmid">10421835</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anthonisen</surname><given-names>NR</given-names></name><name><surname>Manfreda</surname><given-names>J</given-names></name><name><surname>Warren</surname><given-names>CP</given-names></name><name><surname>Hershfield</surname><given-names>ES</given-names></name><name><surname>Harding</surname><given-names>GK</given-names></name><name><surname>Nelson</surname><given-names>NA</given-names></name></person-group><article-title>Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease</article-title><source>Ann Intern Med</source><year>1987</year><volume>106</volume><fpage>196</fpage><lpage>204</lpage><pub-id pub-id-type="pmid">3492164</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Akl</surname><given-names>EA</given-names></name><name><surname>Grant</surname><given-names>BJ</given-names></name><name><surname>Guyatt</surname><given-names>GH</given-names></name><name><surname>Montori</surname><given-names>VM</given-names></name><name><surname>Schunemann</surname><given-names>HJ</given-names></name></person-group><article-title>A decision aid for COPD patients considering inhaled steroid therapy: development and before and after pilot testing</article-title><source>BMC Med Inform Decis Mak</source><year>2007</year><volume>7</volume><fpage>12</fpage><pub-id pub-id-type="pmid">17504536</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buist</surname><given-names>AS</given-names></name><name><surname>McBurnie</surname><given-names>MA</given-names></name><name><surname>Vollmer</surname><given-names>WM</given-names></name><name><surname>Gillespie</surname><given-names>S</given-names></name><name><surname>Burney</surname><given-names>P</given-names></name><name><surname>Mannino</surname><given-names>DM</given-names></name><name><surname>Menezes</surname><given-names>AM</given-names></name><name><surname>Sullivan</surname><given-names>SD</given-names></name><name><surname>Lee</surname><given-names>TA</given-names></name><name><surname>Weiss</surname><given-names>KB</given-names></name><name><surname>Jensen</surname><given-names>RL</given-names></name><name><surname>Marks</surname><given-names>GB</given-names></name><name><surname>Gulsvik</surname><given-names>A</given-names></name><name><surname>Nizankowska-Mogilnicka</surname><given-names>E</given-names></name><collab>BOLD Collaborative Research Group</collab></person-group><article-title>International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study</article-title><source>Lancet</source><year>2007</year><volume>370</volume><fpage>741</fpage><lpage>750</lpage><pub-id pub-id-type="pmid">17765523</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Viejo-Banuelos</surname><given-names>JL</given-names></name><name><surname>Pueyo-Bastida</surname><given-names>A</given-names></name><name><surname>Fueyo-Rodriguez</surname><given-names>A</given-names></name></person-group><article-title>Characteristics of outpatients with COPD in daily practice: The E4 Spanish project</article-title><source>Respir Med</source><year>2006</year><volume>100</volume><fpage>2137</fpage><lpage>2143</lpage><pub-id pub-id-type="pmid">16831541</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fritsch</surname><given-names>K</given-names></name><name><surname>Jacot</surname><given-names>ML</given-names></name><name><surname>Klarer</surname><given-names>A</given-names></name><name><surname>Wick</surname><given-names>F</given-names></name><name><surname>Bruggmann</surname><given-names>P</given-names></name><name><surname>Krause</surname><given-names>M</given-names></name><name><surname>Thurnheer</surname><given-names>R</given-names></name></person-group><article-title>Adherence to the Swiss guidelines for management of COPD: experience of a Swiss teaching hospital</article-title><source>Swiss Med Wkly</source><year>2005</year><volume>135</volume><fpage>116</fpage><lpage>121</lpage><pub-id pub-id-type="pmid">15832228</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scanlon</surname><given-names>PD</given-names></name><name><surname>Connett</surname><given-names>JE</given-names></name><name><surname>Wise</surname><given-names>RA</given-names></name><name><surname>Tashkin</surname><given-names>DP</given-names></name><name><surname>Madhok</surname><given-names>T</given-names></name><name><surname>Skeans</surname><given-names>M</given-names></name><name><surname>Carpenter</surname><given-names>PC</given-names></name><name><surname>Bailey</surname><given-names>WC</given-names></name><name><surname>Buist</surname><given-names>AS</given-names></name><name><surname>Eichenhorn</surname><given-names>M</given-names></name><name><surname>Kanner</surname><given-names>RE</given-names></name><name><surname>Weinmann</surname><given-names>G</given-names></name><collab>Lung Health Study Research Group</collab></person-group><article-title>Loss of bone density with inhaled triamcinolone in Lung Health Study II</article-title><source>Am J Respir Crit Care Med</source><year>2004</year><volume>170</volume><fpage>1302</fpage><lpage>1309</lpage><pub-id pub-id-type="pmid">15374846</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pocock</surname><given-names>SJ</given-names></name></person-group><article-title>Safety of drug-eluting stents: demystifying network meta-analysis</article-title><source>Lancet</source><year>2007</year><volume>370</volume><fpage>2099</fpage><lpage>2100</lpage><pub-id pub-id-type="pmid">18156025</pub-id><pub-id pub-id-type="pmid">18156025</pub-id></citation></ref><ref id="B62"><citation citation-type="book"><person-group person-group-type="author"><name><surname>Deeks</surname><given-names>JJ</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Egger M, Smith G, Altman D</surname></name></person-group><article-title>Effect measures for meta-analysis of trials with binary outcomes</article-title><source>Systematic Reviews in Health Care</source><year>2001</year><edition>2</edition><publisher-name>London: BMJ Publishing Group</publisher-name><fpage>313</fpage><lpage>335</lpage></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>LA</given-names></name><name><surname>Tierney</surname><given-names>JF</given-names></name></person-group><article-title>To IPD or not to IPD? Advantages and disadvantages of systematic reviews using individual patient data</article-title><source>Eval Health Prof</source><year>2002</year><volume>25</volume><fpage>76</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">11868447</pub-id></citation></ref></ref-list></back></article>